Boryung proactively seeks opportunities to partner with pharmaceutical and biotechnology companies in South Korea and overseas.

Boryung appears to be in full swing after signing a co-distribution agreement with HK inno.N for 'K-CAB' and the four items of 'Kanarb' series at the end of last year.

Pharmaceutical industry experts anticipate that Boryung could achieve synergy, including external growth, portfolio expansion, and strengthening its capacity in a vulnerable market, through a co-promotion expansion strategy.

Joint distribution of breast cancer treatment 'Nerlynx'…Boryung strengthens its anticancer therapy portfolio

Boryung reported on